KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Capital Expenditures (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Capital Expenditures for 11 consecutive years, with $517000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 134.63% to $517000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $914000.0 through Dec 2025, up 493.51% year-over-year, with the annual reading at $914000.0 for FY2025, 493.51% up from the prior year.
  • Capital Expenditures hit $517000.0 in Q4 2025 for CRISPR Therapeutics AG, up from $74000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $65.0 million in Q3 2021 to a low of -$64.2 million in Q4 2021.
  • Historically, Capital Expenditures has averaged $2.4 million across 5 years, with a median of $612000.0 in 2024.
  • Biggest YoY gain for Capital Expenditures was 23277.34% in 2021; the steepest drop was 11789.25% in 2021.
  • Year by year, Capital Expenditures stood at -$64.2 million in 2021, then skyrocketed by 150.28% to $32.3 million in 2022, then plummeted by 124.81% to -$8.0 million in 2023, then surged by 81.35% to -$1.5 million in 2024, then skyrocketed by 134.63% to $517000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CRSP at $517000.0 in Q4 2025, $74000.0 in Q3 2025, and $117000.0 in Q2 2025.